Arca
Skip to content
Tools
Tools

Severe combined immunodeficiency

Drug research and approvals for severe combined immunodeficiency: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 11 studies of severe combined immunodeficiency are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, FDA has 2 approved and 7 open orphan designations naming it, and the EU has 1 authorised medicine for it.

  • Recruiting worldwide: 11
  • Trials authorized in Canada: 0
  • FDA orphan approvals: 2
  • EU medicines: 1

Recruiting now

Newest posted first, of 11 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 2

Phase 3 1

Phase 2 7

Phase 1 or earlier 5

How its trials ended

72 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 16 whose ending is known, 38% met their primary endpoint, 0% missed it and 63% stopped early.

  • Ongoing2738%
  • Completed, result not reported2332%
  • Met its primary endpoint68%
  • Stopped: other or unclear68%
  • Status unknown68%
  • Stopped: enrollment or feasibility34%
  • Stopped: lack of efficacy11%

FDA orphan designations

Approved first, then open designations, newest first
Oct 5, 2018RevcoviTreatment of Adenosine Deaminase-Severe Combined Immunodeficiency (ADA-SCID).Chiesi USA Inc.Approved
Mar 21, 1990AdagenFor enzyme replacement therapy for ADA deficiency in patients with severe combined immunodeficiency.Sigma-tau Pharmaceuticals, Inc.Approved
May 3, 2026Autologous CD3delta severe combined immune deficiency…Treatment of severe combined immunodeficiency (SCID)University of California, Los AngelesDesignated
Sep 17, 2024Autologous CD34+ cells transduced with a lentiviral vector…Treatment of severe combined immunodeficiency (SCID)Videja B.V.Designated
Jun 20, 2023Autologous CD34+ hematopoietic stem and progenitor cells…Treatment of patients with Artemis-deficient Severe Combined ImmunodeficiencyMorton J Cowan, M.D.Designated
Sep 18, 2020Mobilized peripheral blood-derived autologous CD34+…Treatment of severe combined immunodeficiencyMustang Bio, Inc.Designated
Aug 31, 2020Firolimogene autotemcelTreatment X-linked severe combined immunodeficiency.Mustang Bio, Inc.Designated
Oct 21, 2014Autologous bone marrow CD34+ cells transduced ex vivo with…Treatment of adenosine deaminase deficient severe combined immunodeficiencyDonald B. Kohn, M.D.Designated
Aug 26, 2009Autologus CD34+ cells transfected with retroviral vector…Treatment of severe combined immunodeficiency due to adenosine deaminase deficiency.Fondazione Telethon ETSDesignated

Medicines authorised in the EU

Newest first
AuthorisedMedicineHolderEPAR
May 26, 2016StrimvelisAutologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence · orphanFondazione Telethon ETSEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.